SCHEMBL3560468

SCHEMBL3560468

O=C(Nc1ccc(Cl)cc1)NC(C(=O)Nc1ccc(-c2cccc[n+]2[O-])cc1)c1ccccc1SC(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
PCTP Q9UKL6 7/20 0.36
UTS2R Q9UKP6 2/20 0.35
CNR1 P21554 6/20 0.34
POLB P06746 1/20 0.33
STARD7 Q9NQZ5 1/20 0.33
STARD10 Q9Y365 1/20 0.33
IDH2 P48735 1/20 0.32
IGF1R P08069 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576235 0.88 MEN1 (0.48) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3559165 0.85 CNR1 (0.38) MEN1MAPTKMT2APCTPUTS2R
SCHEMBL3568269 0.85 CNR1 (0.38) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3560100 0.85 PCTP (0.45) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3561430 0.84 PCTP (0.38) LMNASMN1; SMN2MEN1NPC1KMT2A
SCHEMBL3557410 0.83 UTS2R (0.38) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3562246 0.83 CNR1 (0.40) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3560707 0.82 PCTP (0.48) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3560465 0.81 PCTP (0.34) LMNASMN1; SMN2MEN1NPC1MAPT
SCHEMBL3566091 0.80 UTS2R (0.41) LMNASMN1; SMN2MEN1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 LMNA 938/4885SMN1; SMN2 4448/4885MEN1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.